The effect of perendoscopic sclerosing agent injection in Forrest's II ulcers- A pilot study from Turkey

Simple item page
dc.contributor.authorSaruc M.
dc.contributor.authorOzden N.
dc.contributor.authorKucukmetin N.
dc.contributor.authorTuzcuoglu I.
dc.contributor.authorYuceyar H.
dc.date.accessioned2024-07-22T08:25:12Z
dc.date.available2024-07-22T08:25:12Z
dc.date.issued2002
dc.description.abstractBackground: We aimed to clarify the outcome of perendoscopic prophylactic injection of sclerosing agent in Forrest's II ulcers. Material/Methods: Patients with upper gastrointestinal bleeding in last 6 hours were performed emergency endoscopy and were enrolled. The patients in group-1 were performed prophylactic injection therapy with 1% aethoxysclerol and then given medical treatment with intravenous 40 mg omeprazole twice a day and somatostatin infusion at the dose of 6 mg/day during 3 days. Group-2 patients were only given medical treatment with same agents and at same doses without having any perendoscopic therapy. Results: There were 32 patients in group-1 and 20 in group-2. In emergency endoscopy, 20 (62.5%) patients had IIa ulcers and 12 (37.5%) patients had IIb ulcers in group-1. These patients underwent prophylactic perendoscopic hemostasis by 1% aethoxysclerol in addition to medical treatment. Early rebleeding occurred in 9 (28.1%) patients of group-1 and 3 (15%) in group-2 (p<0.001). At the endoscopic control after 48 hours 13 (40.6%) patients in the group-1 and 15 (75%) patients in group-2 showed improved local ulcer stigmata (p<0.001). The numbers of blood units transfused were lower in the group-2 (p=0.002). The hospital stay was longer in group-1 (p=0.01). In the group-1, more endoscopic intervention was needed. Any death and the need for surgical intervention did not occurred in any groups. Conclusion: According to our results; the indication of perendoscopic prophylactic injection of sclerosing agent in non-bleeding ulcers with high risk of rebleeding must be reviewed by large population based, prospective, radomized trials.
dc.identifier.issn12341010
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20309
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAnti-Ulcer Agents
dc.subjectEndoscopy
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPeptic Ulcer
dc.subjectPilot Projects
dc.subjectSclerosing Solutions
dc.subjectTurkey
dc.subjectomeprazole
dc.subjectpolidocanol
dc.subjectsclerosing agent
dc.subjectsomatostatin
dc.subjectantiulcer agent
dc.subjectadult
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectendoscopic sclerotherapy
dc.subjectendoscopy
dc.subjectfemale
dc.subjectgastrointestinal hemorrhage
dc.subjecthemostasis
dc.subjecthospitalization
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectpeptic ulcer
dc.subjectpilot study
dc.subjectprophylaxis
dc.subjecttreatment indication
dc.subjecttreatment outcome
dc.subjectTurkey (republic)
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectmiddle aged
dc.subjectpeptic ulcer
dc.titleThe effect of perendoscopic sclerosing agent injection in Forrest's II ulcers- A pilot study from Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu